Pfizer Oral GLP-1 Danuglipron Dropped After 73% Nausea and One Liver Injury Case Among 1,400 Patients
Pfizer has pulled the plug on danuglipron (PF-06882961), its experimental once-daily oral GLP-1 receptor agonist for weight management, after a participant in an early-stage dose-optimization trial developed potential drug-induced liver injury (DILI).